Market overview

Global AI in oncology Market size and share is currently valued at USD 1.5 billion in 2024 and is anticipated to generate an estimated revenue of USD 16.4 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 29.70% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 - 2034

Artificial intelligence (AI) is moving from experimental pilot projects into clinically meaningful workflows across oncology. From image-based detection and automated pathology to integrative models that combine genomics, clinical records, and outcomes data, AI tools are being positioned to accelerate diagnosis, personalize treatment selection, and streamline clinical trials. These solutions aim to support clinicians by reducing time-to-diagnosis, improving diagnostic consistency, and uncovering treatment-response signals across large multimodal datasets. Recent regulatory attention, high-profile industry partnerships, and an expanding body of clinical validation studies are pushing AI toward wider translation in cancer care. 

Key market growth drivers

1. Integration of multimodal data for precision oncology — AI models capable of combining imaging, genomic, pathology, and electronic health record data are unlocking more holistic patient profiles that support biomarker discovery and individualized therapy decisions. These integrative approaches are particularly valuable in complex tumor types where single-modality signals are insufficient. 

2. Automation and efficiency gains in diagnostic workflows — Pathology and radiology departments are adopting AI to automate repetitive tasks (triage, pre-screening of slides, auto-segmentation), which helps address workforce shortages and reduces turnaround times for critical oncology diagnostics. 

3. AI-enabled drug development and trial optimization — Pharmaceutical and biotech organizations are using AI to identify novel targets, optimize cohort selection, and improve trial design. High-profile collaborations between drugmakers and AI firms illustrate how machine learning is being embedded into the early and translational stages of oncology R&D. 

4. Regulatory clarification and device authorization pathways — Regulatory agencies are formalizing guidance and maintaining registries of AI-enabled medical devices, offering clearer pathways for clinical authorization and adoption. This regulatory progress reduces uncertainty for purchasers and accelerates clinical deployment when safety and performance are demonstrated. 

Market research methodology

The findings and viewpoints summarized in this article are derived from a mixed-method research approach designed to surface technological trends, clinical adoption patterns, and buyer priorities:

1. Primary stakeholder interviews — Conversations with oncologists, pathologists, radiologists, hospital CIOs, clinical trial specialists, and AI developers to capture firsthand accounts of use cases, operational barriers, and return-on-effort considerations.

2. Clinical literature and validation review — Systematic scanning of peer-reviewed studies, clinical validation papers, and preprint literature that document algorithm performance across tumor types and imaging modalities. This helps distinguish early-stage prototypes from tools with clinical utility.

3. Technology and regulatory scan — Analysis of regulatory resources, device authorization lists, and guidance documents to understand approval pathways and post-market surveillance expectations for AI-enabled oncology tools.

4. Use-case mapping and deployment snapshots — Examination of representative real-world deployments (diagnostic labs, imaging centers, oncology clinics, and clinical trial programs) to assess workflow integration needs, interoperability gaps, and infrastructure demands.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

https://www.polarismarketresearch.com/industry-analysis/ai-in-oncology-market 

Regional analysis

Adoption patterns vary by region, reflecting healthcare infrastructure, reimbursement environments, and regulatory frameworks:

• North America: Early and concentrated adoption in academic medical centers and large health systems where investment in digital pathology, imaging, and genomics infrastructure supports pilot-to-production transitions. Private–public partnerships and venture investment activity also tend to cluster here.

• Europe: Strong emphasis on clinical validation and data privacy; vendors often need region-specific data governance and local hosting options. National health systems and academic networks support collaborative validation studies, while regulators emphasize patient safety in AI device evaluations.

• Asia Pacific: Rapidly expanding infrastructure in major urban centers and strong interest in AI for population-scale screening and diagnostic efficiency. Diverse market maturity creates opportunities for both high-end precision solutions and cost-effective screening tools.

• Latin America, Middle East & Africa: Adoption is uneven—urban tertiary centers and specialized oncology clinics drive demand for advanced tools, while resource-constrained settings prioritize solutions that are robust, low-footprint, and relevant to local disease burdens.

Key companies

• Azra AI
• IBM
• Siemens Healthcare GmbH
• Intel Corporation
• GE HealthCare
• NVIDIA Corporation
• Digital Diagnostics Inc.
• ConcertAI
• Median Technologies
• PathAI

Conclusion

AI in oncology is at an inflection point: growing clinical evidence, clearer regulatory pathways, and active partnerships between technology, life-science, and clinical organizations are moving the field from promise to practical impact. To realize that potential, stakeholders should prioritize rigorous validation across representative populations, plan for seamless integration with existing clinical systems, and align AI initiatives with clear clinical questions—whether that’s earlier detection, better treatment matching, or more efficient clinical trials. When these conditions are met, AI can become a force multiplier for oncology care, helping clinicians deliver more timely, personalized, and data-driven treatment for patients worldwide.

More Trending Latest Reports By Polaris Market Research:

Conjunctivitis Treatment Market

Space Situational Awareness Market

Artificial Intelligence Market

Neurostimulation Devices Market: An Electrical Stimulation Technology to Cure Several Conditions

Space Situational Awareness Market

Cosmetic Surgery Market

Multiplex Assays Market

U.S. Viral Vector and Plasmid DNA Manufacturing Market : Predicted to Reach US$ 11,315.21 Million by 2032 | CAGR 19.9%

GPU as a Service market